Lek strengthens its diversity and inclusion culture

  • By signing the Slovenia Diversity Charter, Lek has joined more than 7,600 organisations across Europe that understand the positive impact of diversity management.
  • Novartis is already implementing various diversity policies through the Diversity and Inclusion initiative.
  • Slovenia was the 20th signatory in a row to join the European Diversity Charter platform; Lek adheres to all principles of the Charter.
14. 11. 2017

Samo Roš, Member of the Board of Management and Head Human Resources of Lek d.d., signed at today’s ceremony, held under the patronage of the President of the Republic of Slovenia Borut Pahor, the Slovenia Diversity Charter. With this act, the pharmaceutical company Lek has also formally joined the community of companies that understand the importance and positive economic impact of diversity management.

Lek adheres to all six principles of the Diversity Charter which are: develop an organisational culture that is based on equal opportunities, mutual respect, acceptance and integration of diverse associates; create a diverse and inclusive work environment; foster and disseminate principles of diversity at all levels of the organisation; acknowledge diversity of customers; develop a diversity policy; and disseminate and communicate its commitment to the principles of diversity and policy thereof to all stakeholders. 

Lek has been fostering the culture of diversity and inclusion for a long time. Novartis associates are now being integrated into the global Diversity and Inclusion initiative, which was originally related to the integration of women but then gradually gained a larger dimension. By promoting diversity, Novartis today supports inclusion of people with different backgrounds, regardless of their way of thinking and management style, gender, race, religion, age, experience, etc. A diverse company consisting of individuals, who respect one another, trust each other, accept different ideas and views, is more innovative, productive and successful.

Nejc Jaka Sekula, head of Diversity and Inclusion at Lek: »For us as a company, signing this Charter represents a commitment to continue work in this field and to foster the diversity and inclusion culture in all parts of the company. Only in this way, we can encourage individuals and groups to realise their potential and contribute their unique experience and views, and thus provide an innovative environment that enables personal growth and development as well as growth and development of the company. In this way, we are providing the right environment for talents who want to work in a caring organisation.«

The Slovenia Diversity Charter is based on voluntary accepted principles aimed at promoting the values of diversity, equality and inclusion. It promotes the implementation of diversity policies within Slovenian companies with the purpose of recognising, understanding, respecting and including diversity as a potential source of innovation for sustainable solutions for organisations.
The Slovenia Diversity Charter was the 20th in a row to join the European platform of Diversity Charters, which brings together more than 7,600 organisations. It was developed under the auspices of the Slovenian partnership’s project I.D.E.A.S. (Dobrovita, Šentprima, SKUP, ZDS, ZIZRS, MDDSZ, CNVOS), in cooperation with the European Commission, Directorate General for Justice and Consumers.

* * *

Lek, a Sandoz company, is one of the key pillars of the second-largest generic pharmaceutical company globally. Its role within Sandoz is to act as: a leading global development center for technologically demanding products and technologies; a key global manufacturing center for active pharmaceutical ingredients and medicines; a competence center for the development of vertically integrated products; a Sandoz competence center in the field of development and manufacturing of biosimilar active ingredients and products; a supply center for the markets of Central and Eastern Europe (CEE), South East Europe (SEE) and the Commonwealth of Independent States (CIS), and is responsible for marketing and sales of Sandoz products on the Slovenian market. For further information, please visit www.lek.si.

Sandoz is a global leader in generic and biosimilar pharmaceuticals. As a division of the Novartis Group, our purpose is to discover new ways to improve and extend people’s lives. We contribute to society’s ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine. Our portfolio of approximately 1000 molecules, covering all major therapeutic areas, accounted for 2016 sales of USD 10.1 billion. In 2016, our products reached more than 500 million patients and we aspire to reach one billion. Sandoz is headquartered in Holzkirchen, in Germany’s Greater Munich area.
Sandoz is on Twitter. Sign up to follow @Sandoz_global at http://twitter.com/Sandoz_Global (link is external).

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. In 2016, the Group achieved net sales of USD 48.5 billion, while R&D throughout the Group amounted to approximately USD 9.0 billion. Novartis Group companies employ approximately 121,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world. For more information, please visit http://www.novartis.com.

* * *

This press release contains statements and conclusions based on projections of Lek’s future business operations. These estimates are derived from the best information currently available. In case these forecasts prove unreliable, the actual results could prove different from those projected.

- end -

For additional information contact:
Katarina Klemenc
Corporate Communications 
Lek Pharmaceuticals d. d.
Phone: +386 1 580 22 43
Fax: +386 1 580 24 32